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Chemotherapeutic treatment for Canine transmissible venereal tumor (CTVT) commonly relies on vincristine
administration. Since the treatment outcomes can vary among CTVT cases, gaining insight into the tumor cell
mechanisms inﬂuencing vincristine's potency should render veterinarians novel knowledge to enhance its ther-
apeutic effect. This study aimed to attain such knowledge from a meta-analysis of CTVT mRNA sequencing
(mRNA-seq) transcriptome data using Factor Analysis for Bicluster Acquisition (FABIA) biclustering.
FABIA biclustering identiﬁed 459 genes consistently expressed among mRNA-seq transcription proﬁling of
CTVT samples regressed by vincristine. These genes were also differentially expressed from those of progressive
CTVT (FDR  0.001). Enrichment analysis illustrated the afﬁliation of these genes with “Antigen presentation”
and “Lysosome” GO terms (FDR  0.05). Several genes in “Lysosome” term involved 5 cell mechanisms—antigen
presentation, autophagy, cell-adhesion, lysosomal membrane permeabilization (LMP), and PI3K/mTOR signaling.
This study integrated FABIA biclustering in CTVT transcriptome analysis to gain insight into cell mechanisms
responsible for vincristine-sensitive characteristics of the tumor, in order to identify new molecular targets
augmenting therapeutic effect of vincristine. Interestingly, the analysis indicated LMP targeting by lysosome
destabilizing agent—siramesine as the promising vincristine's enhancer for future study. As far as we know, this is
the ﬁrst canine tumor transcriptomic meta-analysis applying FABIA biclustering for the betterment of future CTVT
therapy. This study hereby provided an interesting manifestation to acquire such knowledge in other canine
neoplasia.1. Introduction
Canine transmissible venereal tumor (CTVT) is a unique contagious
canine neoplasia transmissible via mucosal contact and abrasions as
allograft (Das and Das, 2000). CTVT progression is indexed by its growth
rate along with its histopathological feature (Birhan and Chanie, 2015;
Islam et al., 2017). In progressive phrase, CTVT mass grows rapidly
within a week bestowing active round tumor cells showing signiﬁcant
diffused hyperchromatic nuclei and mitotic ﬁgures. In response to
effective treatment or immunity, CTVT would attain stable phrase
impairing its growth rate from weeks to months. Finally, it would man-
ifest marked regression in the regressive phrase, during which the active
tumor cells were evanescent (Islam et al., 2017; Park et al., 2006).
Most CTVT cases are progressive with undeﬁned tumor mechanismsnanmuang).
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vier Ltd. This is an open access a(Birhan and Chanie, 2015; Frampton et al., 2018; Siddle and Kaufman,
2015). In most human tumors, aberrant control of several cell mecha-
nisms were acknowledged during tumor progression. Some of these
mechanisms, for instance, cell adhesion (Besson et al., 2008; Li, 2008),
autophagy (Crotzer and Blum, 2009), cyclin-dependent kinase (CDK)
inhibtion (Besson et al., 2008), and lysosomal membrane permeabiliza-
tion (LMP)-induced cell death (Groth-Pedersen et al., 2007; Serrano--
Puebla and Boya, 2018) were recently acclaimed as novel targets for
tumor therapy. On the contrary, the tumor feedback mechanisms to some
well-recognized tumor drugs, such as, phosphatidylinositol-3-kinase
(PI3K) and the mammalian target of rapamycin (mTOR)—the PI3K/m-
TOR signaling inhibitors (Stratikopoulos and Parsons, 2016), and resis-
tance to anti-mitotic agent (Birhan and Chanie, 2015; Report et al., 2012)
currently became the critical therapeutic issues. While contributing rolesApril 2019
rticle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
CTVT datasets used in this study.
Datasets Phrase of CTVT
biosample
Day after vincristine treatment
(0.025 mg/kg)
ERR1846288 Regressive Day 14
ERR1846291 Regressive Day 14
ERR2044814 Regressive Day 28
ERR2044816 Regressive Day 28
ERR2044818 Regressive Day 28
ERR1846287 Progressive None
ERR1846290 Progressive None
ERR2044811 Progressive None
ERR2044812 Progressive Day 28
ERR2044813 Progressive None
ERR2044815 Progressive None
ERR2044817 Progressive None
ERR2044819 Progressive None
ERR2044820 Progressive Day 28
ERR2044821 Progressive None
ERR2044822 Progressive Day 28
ERR1846289 Stationary Day 6
ERR1846292 Stationary Day 6
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edged, gaining insight into them should provide us clues for the better-
ment of future CTVT therapy.
Vincristine sulfate is the well-known anti-mitotic agent of choice
against CTVT (Das and Das, 2000; Report et al., 2012). By binding to
tubulin spindle ﬁber, vincristine can arrest tumor chromosome segrega-
tion at metaphase stage (Jordan, 2012). In human neoplasia,
vincristine-induced cell death was additionally evidenced to afﬁliate
with LMP-induced cell death (Groth-Pedersen et al., 2007; Serrano--
Puebla and Boya, 2018). However, such mechanism was not clearly
veriﬁed in CTVT. Despite its efﬁciency, evidences of CTVT resistant cases
were accumulated. This emphasized the necessity to understand CTVT
resistant mechanisms for better therapeutic regimens to cope with them
(Das and Das, 2000; Report et al., 2012; Rogers et al., 1998). Interest-
ingly, recent advance in CTVT mRNA sequencing provided us an op-
portunity to gain insight into such cryptic mechanisms (Frampton et al.,
2018).
Tumors in different phrases render different transcription proﬁles
distinct from one another. It is hereby supportive of CTVT regressed by
vincristine to demonstrate unique transcription patterns of mRNA
sequencing data and vice versa. In order to discover such transcript
patterns, Factor analysis for bicluster acquisition—FABIA was considered
as a powerful data mining technique to extract such knowledge from
transcriptome data (Eren et al., 2013). FABIA allowed simultaneous
clustering of both tumor samples and their transcripts even with presence
of minor differences, and thus was able to capture the correlated tran-
scripts among undeﬁned sample subsets with small bias (Eren et al.,
2013; Hochreiter et al., 2010). Such co-clustering of sample subsets and
gene transcripts—the biclusters could point out even the small changes in
biological pathways modulated among tumor cells in different conditions
(Besson et al., 2008; Skonieczna et al., 2017; Stratikopoulos and Parsons,
2016). Despite its absence of application in CTVT transcriptome studies,
FABIA should be effective in identifying the vincristine-responsive
transcript patterns of CTVT. By means of this, the acquired biclustering
genes would further imply tumor cell mechanisms which could hint us
novel approach to induce CTVT regression.
In this study, FABIA biclusters of vincristine-responsive CTVT tran-
scription proﬁles were identiﬁed. Several of these genes encoded lyso-
somal proteins—of which their functions were associated with particular
cell mechanisms and their vincristine-sensitive features. Unlike the pre-
vious study which concentrated on describing tumor genetic background
and host-tumor interaction (Frampton et al., 2018), this study aimed to
gain insight into noteworthy cell mechanisms responsible for
vincristine-induced CTVT regression. With the acquired knowledge,
novel chemotherapeutic approaches were introduced providing exiting
several open-topics for future studies of CTVT therapy.
2. Materials and methods
2.1. Sample datasets
List of CTVT mRNA sequencing datasets used in this study were
generated from NextSeq sequencing technology, and were freely avail-
able in Sequence Read Archive (SRA) database (https://www.ncbi
.nlm.nih.gov/sra). The SRA datasets and their descriptions were pro-
vided (Table 1). In brief, CTVT samples used for dataset generation were
acquired 3 tumor phrases—regressive, progressive and stationary phra-
ses. Of note, all CTVT samples in regressive phrase were obtained after
vincristine treatment. Further details of each dataset could be achieved
directly from SRA database.
2.2. Data preprocessing
The Sequence Read Archive (SRA) ﬁles of CTVT mRNA sequencing
datasets were retrieved from SRA database (https://www.ncbi.nlm.nih
.gov/sra) (Table 1), subsequently extracted, and pre-processed similar2to those previously described (Chokeshaiusaha et al., 2018a, 2018b,
2016) In brief, sequence trimming was performed by Cutadapt program
to remove contaminated adapter sequences and unqualiﬁed sequences.
Only sequences with length 25 nucleotides and mean Phred score 25
were selected for canine genome—CanFam3.1 alignment by STAR soft-
ware. Duplicated sequences were remove and corrected for GC base
balance. Gene-level counting was performed by HTSeq software
following by regularized-logarithm transformation and batch correction
to normalize all count read datasets.2.3. Differential biclustering genes
Factor analysis for bicluster acquisition (FABIA) was performed with
the pre-processed CTVT datasets using “fabia” package (Hochreiter et al.,
2010). The expected bicluster numbers ranged from 1 to 3 biclusters
according to the number of CTVT phrases, and only biclusters containing
with all tumor samples of their phrases would be considered (1,000 it-
erations and α  0.01). Gene-level deferential expression analysis be-
tween regressive and progressive CTVTs was performed by DESeq2
package (FDR  0.001 and log2-fold-change  2) (Love et al., 2014).
Only differentially expressed genes presented in the acquired biclusters
would be considered and included in gene-annotation enrichment
analysis.2.4. Gene-annotation enrichment analysis
Functional properties of the acquired differential biclustering genes
were evaluated by gene-annotation enrichment analysis using ‘goseq’
package (Young et al., 2010). By available human-dog orthologous
genes, signiﬁcant Gene Ontology (GO) terms of both species were
extracted from GO consortium database (FDR  0.05).2.5. Data virtualization
Principal Component Analysis (PCA) was performed on pre-processed
datasets and plot for virtualization in 3-dimensions as previously
described (Chokeshaiusaha et al., 2016). Circular and combined heat-
maps were drawn by ‘circlize’ (Gu et al., 2014) and ‘ComplexHeatmap’
packages (Gu et al., 2016), respectively. To present signiﬁcant canine and
human Gene Ontology—GO terms pertained from enrichment analysis,
the word clouds were generated using ‘Gosummaries’ package (Kolde
and Vilo, 2015).
Fig. 2. The circular heatmap demonstrated differential FABIA biclustering
genes (columns) of CTVT samples (rows) grouped by phrases—R for regressive,
P for progressive, and S for stationary phrases, accordingly. The genes were
divided into 2 groups, low and high expression groups—according to their
expression levels in regressive CTVT.
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3.1. FABIA biclustering was able to discover unique gene expression
patterns of regressive CTVT samples
Principal Component Analysis (PCA) revealed separate clusters of
regressive and progressive CTVT samples with stationary CTVT samples
scattered among them—implying the differences in nature of CTVT
transcriptome between regressive and progressive phrases. On the con-
trary, clustering of stationary CTVT samples was not presented (Fig. 1).
Interestingly, FABIA biclustering successfully provided a solid bicluster
containing overall regressive CTVT samples. Among expressed genes
presented in the bicluster of regressive CTVT, 459 genes were found
differentially expressed from those of progressive CTVT samples (FDR 
0.001 and log2-fold-change  2). We did not include stationary CTVT in
the analysis due to their inadequate sample numbers. These selected
genes could be clearly classiﬁed into high and low expression groups
concerning their relative expression levels in regressive CTVT (Fig. 2).
3.2. Enrichment analysis of acquired differential biclustering genes
revealed “Antigen presentation” and “Lysosome” terms strongly associated
with the transcript pattern of regressive CTVT
Gene-annotation enrichment analysis revealed mutual signiﬁcant
terms achieved from both canine and human GO consortium databases,
especially the 3 common terms—antigen processing and presentation,
MHC class II protein complex (Fig. 3A), and lysosome (Fig. 3B) (FDR 
0.05). All genes presented in the “MHC class II protein complex” term
were also in the “Antigen processing and presentation”, by which several
genes were diminished in regressive CTVT, especially the canine MHC
class II genes—the Dog Leukocyte Antigen (DLA) class II genes—DLA-
DQA1, DLA-DMA, DLA-DRA, DLA-DMB (Fig. 4A). In addition, expres-
sions of 2 DLA class I genes—DLA-79, and DLA-88 were also low in
regressive CTVT. Interestingly, homogeneous expressions of numerous
genes presented in the lysosome term were also manifested in regressive
CTVT (FDR  0.05) (Fig. 4B). While most of these genes were directly
concerned with lysosomal function, several of them linked to other tumor
cell mechanisms and features, by which would be further described in
details.
Numbers of enzyme-encoding genes—ARSB, ASAH1, DPP7, DNASE2,
FUCA1, GGH, GLA, GUSB, HEXB, IL4I1, LIPA, and PPT1, along with
lysosome marker gene—TM6SF1 were lesser expressed in regressive
CTVT despite some minor exceptions—SIAE and PNPLA7. These en-
zymes functioned in endosome, lysosome, phagosome, and autophago-
some during autophagy (Anding and Baehrecke, 2017; Crotzer and Blum,32009; Pasquier, 2016; Pearson and Soleimanpour, 2018). Expression
heparan sulfate degrading-enzymes—GNS, HPSE, NAGLU were also
diminished, while expressions of lysosomal membrane permeabilized
proteases in cathepsin family—CST3, CTSF, CTSH, CTSK, CTSS, CTSW
and CTSZ were varied.
Not only the enzyme-encoding genes, other genes in the “lysosome”
term with indicated the functions related with some crucial cell mecha-
nisms were also noticeable. These included PI3K/mTOR-associated
genes—LRRK2, NPRL2, DEPDC5, TSC2, HCK, HGS, KPTN, RPTOR,
RUBCN, SZT2 and MTOR; sorting/transpoort-protein genes—CHMP2B,
CLN5, DOC2A, GM2A, LMBRD1, NPC2, SNX2, and TMEM79; autophagy-
regulating genes— CHMP2B, GABARAP, LAMP2, MCOLN3, UVRAG, and
VAMP8; and even antigen presentation-associated genes—ABCB9, CD74,
and TMEM175.Fig. 1. The Principle Component Analysis (PCA) results of
CTVT samples were presented in 3-dimensional plot. The
x, y and z axes represented the principal component 1
(PC1), principal component 3 (PC3), and principal
component (PC2) values, accordingly. The blue rectangles,
red circles, and yellow triangles respectively represented
regressive, progressive, and stationary CTVT samples.
Clusters of regressive CTVT (blue sphere) and progressive
CTVT (red sphere) were presented, while stationary CTVT
samples seemed to scatter between the two clusters.
Fig. 3. The word-clouds of canine (3A) and human (3B) GO annotation terms were generated from the differential biclustering genes. The term labels were plotted
with their sizes proportional to numbers of genes presented, and with their colors ranged by their FDR values acquired from enrichment analysis.
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genes associated with antigen presentation, autophagy, cell-adhesion,
lysosomal membrane permeabilization (LMP), and PI3K/mTOR signaling
According to the previous result, categorization of differential
biclustering genes in the “lysosome” term suggested 5 major cell mech-
anisms related with biclustering genes of regressive CTVT. These cell
mechanisms were as follows—antigen presentation, autophagy, cell-
adhesion, lysosomal membrane permeabilization (LMP), and PI3K/
mTOR signaling. We hereby included more differential biclustering
genes with considerable roles in such mechanisms additional to those
presented in lysosome term. While some genes were associated with
several terms, we categorized them accordingly for simplicity. The
overall genes, including those presented in lysosome term were catego-
rized and separately demonstrated for convenient inspection (Fig. 5).
Most of additional genes were associated with PI3K/mTOR pathway, and
were expressed in regressive CTVT with signiﬁcant levels—AKT1S1,
BRD4, ESR1, PIK3R1, RICTOR, RPTOR, and TYRO3 (except for STAT1)
(Fig. 5). Regressive CTVT also expressed signiﬁcant LIMK2—an actin
ﬁlament controlling gene affecting cell-to-cell adhesion (Fig. 5).
4. Discussion
Redundant cell mechanisms are common among tumor cells despite
their comparable phrases or stages (Lavi, 2015). Varied genome-wide
transcription patterns among CTVT samples even in the same phrase
were thus common (Fig. 1). It was hereby reasonable that unique cell
mechanisms modulated in each CTVT phrase should be denoted by its
homogeneous transcript pattern unique from other phrases. In this study,
FABIA biclustering captured such pattern in vincristine-responsive
regressive CTVT (Fig. 2). Since such gene expression pattern reﬂected
regressive CTVT's uniqueness, the cell mechanisms associated with them
were, at certain degree, responsible for the tumor regression. Beneﬁ-
cially, such acquired knowledge should provide valuable insight into
novel therapeutic agents targeting these cell mechanisms.4.1. CTVT regressed from vincristine demonstrated low DLA class II
antigen presentation
Vincristine-responsive CTVT was generally characterized by
increased tumor cell apoptosis, along with reduced mitotic ﬁgures and
reduced numbers of tumor inﬁltrating lymphocytes (TILs) (Mukaratirwa
et al., 2009). Since IL-6 and IFN-γ secreted by TILs were major stimulants
of DLA expression on CTVT cells (Hsiao et al., 2008), their absence
should partially contribute to poor DLA gene expressions (Fig. 4A), and
other genes associated with antigen processing, loading, and trans-
portation (CTSS, CTSH, and PSMB8) (Fig. 5) in regressive CTVT. It should
be however noted that, greater DLA class II gene expressions in pro-
gressive CTVT should bestow limited effects on spontaneous CTVT4regression—which depended mainly on DLA class I antigen presentation
to cytotoxic TILs (Hsiao et al., 2002; Mukaratirwa et al., 2009; Siddle and
Kaufman, 2015). By mean of this, enhancing TIL function by recent im-
munotherapies, for instance by, autologous pulsed dendritic cell (Fran-
co-Molina et al., 2018) or intratumoral IL-2 (Den Otter et al., 2015a,
2015b) could hereby provide putative synergistic effect with vincristine
treatment.
4.2. Lysosomal membrane permeabilization (LMP) should be integrated
into vincristine-induced CTVT regression
Vincristine was evidenced to sensitize lysosome's permeabilization in
several human tumor cells (Groth-Pedersen et al., 2007; Serrano-Puebla
and Boya, 2018). This resulted in leakage of several enzymes, especially
speciﬁc cathepsins that could promote tumor cell death (Serrano-Puebla
and Boya, 2018). Apart from varied expression of cathepsin-encoding
genes (CST3, CTSF, CTSH, CTSK, CTSS, CTSW, and CTSZ), reduced
lysosomal membrane integrity was also indicated in regressive CTVT
(Fig. 5). To stabilize membrane integrity, Lysosome-associated mem-
brane protein 2 (LAMP2) and Heatshock protein 70 (Hsp70) consolidated
themselves into lysosomal membrane and functioned as major lysosomal
membrane stabilizers (Groth-Pedersen et al., 2007; Serrano-Puebla and
Boya, 2018). Poor expression of LAMP2 in regressive CTVT (Fig. 5)
should hereby increased its sensitivity to LMP and thus susceptibility to
vincristine, accordingly. Interestingly, the suggested LMP synergistic ef-
fect on vincristine endorsed the feasibility of lysosome destabilizing
agents such as siramesine for CTVT therapy. Supporting such idea, sir-
amesine was previously shown to synergize vincristine's effect on human
breast tumor by reducing its dose-toxicity, and even overcoming the
vincristine-resistant tumor cells (Groth-Pedersen et al., 2007). According
to the evidence, we contemplated the favorable effects of siramesine on
CTVT therapy, as well.
4.3. Impaired autophagy should contribute in CTVT's sensitivity to
vincristine
Intracellular degradation of cytoplasmic proteins and organelles by
autophagy is regarded as a fundamental cell mechanism for eliminating
damaged proteins/organelles by lysosomal degradation (Anding and
Baehrecke, 2017). Moreover, autophagy was even considered to provide
particular antigens for MHC class II antigen presentation (Crotzer and
Blum, 2009). Since removal of damaged proteins/organelles both pre-
vented cell from such toxic byproducts and enabled recycle of nutrients
(Anding and Baehrecke, 2017; Crotzer and Blum, 2009; Pasquier, 2016),
autophagy should be considered as an crucial cell mechanism to protect
CTVT cell from proteins/organelles damaged caused by vincristine
(Groth-Pedersen et al., 2007).
Interestingly, differential biclustering genes strongly suggested inef-
ﬁcient autophagy in regressive CTVT. Supporting this notice, expressions
Fig. 4. The heatmap of differential biclustering genes presented in “Antigen
presentation” (4A) and “Lysosome” (4B) GO terms were illustrated. The heat-
map row represented genes clustered by Pearson correlation distance with
complete linkage, while the column represented CTVT samples categorized by
their phrases.
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5of several enzyme-encoding genes required for degrading damaged
molecules in lysosome (ARSB, ASAH1, DPP7, DNASE2, FUCA1, GGH,
GLA, GUSB, HEXB, IL4I1, LIPA, and PPT1) were despicable. Furthermore,
diminished expressions of regressive CTVT's transcripts were also
observed in autophagy regulatory protein-encoding genes (UVRAG (Jo
et al., 2018) and VAMP8 (Chen et al., 2015)), autophagosome sorting/-
channeling protein-encoding genes (CHMP2B (Krasniak and Ahmad,
2016), GABRAP (Nguyen et al., 2016) and MCOLN3 (Sun et al., 2016))
and even the gene encoding key receptor of chaperone-mediated auto-
phagy—LAMP2 (Crotzer and Blum, 2009) (Fig. 5).
Since autophagy was required for both damaged protein clearance
and antigen presentation, inefﬁcient autophagy in regressive CTVT not
only enhanced its susceptibility to vincristine-induced cell death, but also
aggravated inhibition of DLA class II antigen presentation. Due to the
supportive effect of autophagy suppression on vincristine treatment, we
hereby anticipated its beneﬁt on CTVT therapy by considering inclusion
of autophagy inhibitors. However, it should be noted that, such agents
could not provide exclusive targeting on cell autophagy (Pasquier, 2016),
and thus were likely to cause integratively unpredictable effects when
applied with CTVT.
4.4. Downstream inhibition of PI3K/mTOR signaling was suggested
PI3K/mTOR signaling is a complex cellular network regulating core
cell mechanisms, such as, cell growth, cell proliferation and cell survival
with signiﬁed crosstalks with other cellular signaling (Stratikopoulos and
Parsons, 2016). PI3K/mTOR signaling is thus the major target for
altering regulation in several types of tumors. In this study, downstream
blockade of PI3K/mTOR signaling, albeit signs of increasing signaling
molecules, was implied in CTVT regressed by vincristine. Increasing
signaling molecules were suggested by high expression of PIK3R1 gene,
which encoded p85α—the catalyzer of upstream signaling messen-
ger—the phosphatidylinositol (3,4,5)-trisphosphate (PIP3) (Strat-
ikopoulos and Parsons, 2016). Intensifying mTOR complex 1 and 2
(mTORC1 and mTORC2)—the well-known PI3K/mTOR mediators were
also suggested due to enhanced expression of their component-encoding
genes—RPTOR, RICTOR and MTOR genes (Earwaker et al., 2018; Sar-
bassov et al., 2005) (Fig. 5).
Despite the sign of increasing mediators, putative blockade in
downstream signaling was presumed by high expressions of several
mTORC1 inhibitor-encoding genes—DEPDC5 (Mizuno et al., 2018),
KPTN (Saxton and Sabatini, 2017), NPRL2 (Saxton and Sabatini, 2017),
SZT2 (Galluzzi et al., 2012; Wolfson et al., 2017), and TSC2 (Kang et al.,
2011) (Fig. 5). Since mTORC1 was the key mediator of cell growth,
overexpression of such inhibitors should result growth suppression of
regressive CTVT (Stratikopoulos and Parsons, 2016). Additionally, other
factors possibly contributing to signaling inhibition were also evidenced.
These included enhanced expression of RUBCN—a PI3K
inhibitor-encoding gene (Liu et al., 2017), limited expression of STAT1
mediator-encoding gene, limited expressions of ESR1 and TYRO3—the
PI3K signaling receptor-encoding genes, and ﬁnally, the limited expres-
sions of LRRK2 (Looyenga et al., 2011) and HCK (Poh et al., 2015)—the
receptor associated kinase-encoding genes.
Implied mTORC1 signaling inhibition in vincristine-sensitive CTVT
interestingly suggested certain PI3K/mTOR inhibitor—rapamycin as
CTVT therapeutic agent. Rapamycin is a popular mTOR inhibitor applied
among human tumor cases (Stratikopoulos and Parsons, 2016). Albeit
the expected positive effects of combined vincristine and rapamycin on
CTVT regression, the tumor feedback mechanisms against PI3K/mTOR
inhibitors should also be regarded as possible drug-resistant complica-
tion (Stratikopoulos and Parsons, 2016).
4.5. Rigid cell adhesion was associated with regressive form of CTVT
Reduced adhesion of tumor cells to their adjacent cells and extra-
cellular matrix (ECM) allow migration of progressive tumor (Besson
Fig. 5. The heatmaps of the selected differential biclustering genes associated with 5 target cell mechanisms—Antigen presentation, Autophagy, Cell adhesion,
Lysosomal membrane permeabilization (LMP), PI3K/mTOR signaling were illustrated. The heatmap row represented genes clustered by Pearson correlation distance
with complete linkage, while the column represented CTVT samples categorized by their phrases.
K. Chokeshaiusaha et al. Heliyon 5 (2019) e01558et al., 2008; Report et al., 2012). For cell-to-cell adhesion, induction of
actin stress ﬁbers determines its strength (Sahai et al., 2001). Since
LIM-kinase 2 mediated cell-to-cell adhesion via actin stress ﬁber assem-
bly (Amano et al., 2001), high expression of its encoding gene—LIMK2 in6regressive CTVT (Fig. 5) should thus impaired its progression. Addi-
tionally, regressive CTVT seemed to constitute higher adhesive strength
to ECM than progressive CTVT, as well. ECM structure was majorly
supported by arrays of heparan sulfate proteoglycan. These molecules not
K. Chokeshaiusaha et al. Heliyon 5 (2019) e01558only strengthened cell adhesion, but also helped reserving factors
required for tumor's blood vessel generation. Interestingly, several types
of human tumors secreted heparanase to degrade heparansulfate—both
for loosening ECM adhesion and releasing the trapped growth-promoting
factors (Roy and Marchetti, 2009; Skonieczna et al., 2017). Low ex-
pressions of heparanase-encoding genes, especially HPSE, in regressive
CTVT should hereby help limiting its progression (Fig. 5). By mean of
this, administration of heparanase inhibitors, such as heparin, was likely
to alleviate CTVT progression and metastasis.
5. Conclusions
Vincristine has been recognized as the drug of choice for CTVT
therapy (Birhan and Chanie, 2015). Despite its long-term history of
application, possible tumor cell mechanisms affecting its potency are still
ambiguous. Differential biclustering genes in this study implied 4 cell
mechanisms with consistent modulatory effects on vincristine's poten-
cy—LMP, autophagy, PI3K/mTOR signaling and cell adhesion. The ac-
quired knowledge hereby established novel chemotherapeutic agents
targeting such cell mechanisms to enhance therapeutic effect of vincris-
tine. Owing to the suggested direct involvement of LMP with vincristine
mechanism, we remarked the use of lysosome destabilizing agents, such
as, siramesine as the most attractive approach. Given the success of
vincristine-siramesine combination chemotherapy in human tumors
(Groth-Pedersen et al., 2007; Serrano-Puebla and Boya, 2018), study of
its sole efﬁciency on CTVT regression should be regarded as an exciting
issue for further investigation. Of note, the current study manifested an
original analytical procedure to screen for speciﬁc molecular features in
canine neoplasia using FABIA method—by which similar approach could
be achieved in other tumor studies.
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